The observations that high AMPKα1 activity significantly correlated with poor patient survival [7], and that metformin use in diabetic patients (which in part activates AMPK) reduced the incidence of colorectal cancer [12,13] merit greater scrutiny. This evidence concerns the gene PRKAA1 and colorectal cancer.